Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kashif Jafri

Rheumatology Atlanta, GA Medical Doctor

NPI 1598025884 CMS profile 379873

1800 Howell Mill Rd Nw Ste 500, Atlanta, GA 30318

Open in the dashboard

General payments

$8,682

429 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kashif Jafri of Atlanta, GA is reported in the CMS Open Payments database as having received $8,682 across 429 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,968 91
2024 General $2,056 98
2023 General $2,055 102
2022 General $1,356 74
2021 General $658 35
2020 General $77 4
2019 General $513 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kashif Jafri
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Kashif Jafri were reported at $1,968. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Kashif Jafri Rheumatology median Middle half National median
2019 $513 $744 $153–$2,687 $163
2020 $77 $462 $98–$2,027 $114
2021 $658 $531 $101–$2,153 $132
2022 $1,356 $627 $125–$2,303 $149
2023 $2,055 $741 $145–$2,524 $160
2024 $2,056 $830 $166–$2,660 $164
2025 $1,968 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,537 77 payments
  2. Amgen Inc. $1,136 58 payments
  3. Novartis Pharmaceuticals Corporation $1,023 77 payments
  4. Pfizer Inc. $726 40 payments
  5. UCB, Inc. $661 30 payments
  6. Janssen Biotech, Inc. $649 24 payments
  7. AstraZeneca Pharmaceuticals LP $574 18 payments
  8. GlaxoSmithKline, LLC. $472 22 payments
  9. Horizon Therapeutics plc $286 14 payments
  10. Lilly USA, LLC $225 9 payments
  11. Other $1,396 60 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,486 423 payments
  2. Education $196 6 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $1,129 53 payments
  2. COSENTYX Dermatology $654 42 payments
  3. XELJANZ $572 34 payments
  4. BENLYSTA $472 22 payments
  5. SAPHNELO $448 16 payments
  6. TREMFYA $429 16 payments
  7. COSENTYX Immunology $425 38 payments
  8. Cimzia $406 19 payments
  9. SIMPONI ARIA $325 14 payments
  10. Bimzelx $255 11 payments
  11. Other $4,689 213 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,591

Median for Rheumatology: 1,511

Drug cost

$2,542,146

Median for Rheumatology: $1,139,948

Branded share of claims

36.5%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 124 $911,370
Rinvoq Upadacitinib Brand 65 $461,273
Enbrel Sureclick Etanercept Brand 47 $400,323
Forteo Teriparatide Brand 22 $177,409
Kevzara Sarilumab Brand 26 $135,626
Benlysta Belimumab Brand 25 $118,668
Actemra Actpen Tocilizumab Brand 22 $99,823
Xeljanz Xr Tofacitinib Citrate Brand 14 $87,937
Cosentyx Sensoready (2 Pens) Secukinumab Brand 11 $74,816
Prolia Denosumab Brand 21 $35,514

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$96,504

Of which drugs: $40,693

Medicare patients

206

Average age 73

Services billed

3,104

127 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 71%
Ischemic heart disease 33%
Osteoporosis 33%
Chronic kidney disease 29%
Diabetes 23%
Atrial fibrillation 16%
Depression 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 19 1,980 $40,680

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
COSENTYX
  • Novartis Pharmaceuticals Corporation $249
$249 11 —
XELJANZ
  • PFIZER INC. $178
$178 14 —
RINVOQ
  • AbbVie, Inc. $115
$115 65 —
FASENRA
  • AstraZeneca Pharmaceuticals LP $105
$105 — —
SKYRIZI
  • AbbVie, Inc. $105
$105 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

429 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record